Medication abortion, also referred to as medical abortion, is a safe and effective method of providing abortion. Medication abortion involves the use of medicines rather than uterine aspiration to induce an abortion. The U.S. Food and Drug Administration (FDA)-approved medication abortion regimen includes mifepristone and misoprostol. The purpose of this document is to provide updated ... Read more >

Women at high risk for maternal morbidity and mortality have unique needs for reproductive health services, including prenatal and postpartum care, contraception, and abortion. However, barriers such as restrictive state legislation, poor access to trained providers, limits in insurance coverage, and clinical challenges in assessing and communicating risk often make it difficult for these women ... Read more >

Here you can learn evidence-based ways to: Evaluate patients prior to provision of mifepristone for early abortion or miscarriage management; effectively counsel patients regarding medication abortion; and discuss criteria to determine the need for additional clinical services after use of mifepristone. CME credit is available for completing this 1 hour training.

Barriers to women’s reproductive health care access, particularly for termination of pregnancy, are increasing at the local, regional, and national levels through numerous institutional, legislative, and regulatory restrictions. Lack of access to reproductive health care has negative consequences for women’s health. Twelve women’s health care organizations affirm their support for access to comprehensive reproductive health ... Read more >

This commentary introduces the Medical Abortion Reporting of Efficacy (MARE) guidelines as a supplement to CONSORT and STROBE. The goal of the recommendations is to standardize early medical abortion efficacy reporting to facilitate comparison of outcomes between studies and to enrich the ability for data synthesis from different studies to create evidence-based guidelines. We hope ... Read more >